David A Rodeberg

Summary

Affiliation: East Carolina University
Country: USA

Publications

  1. doi request reprint Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of P
    David A Rodeberg
    Department of Pediatric Surgery, Children s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA
    Int J Cancer 128:1232-9. 2011
  2. pmc Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group
    David A Rodeberg
    Children s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 29:1304-11. 2011
  3. pmc Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee
    Aaron R Weiss
    The Soft Tissue Sarcoma Committee of the Children s Oncology Group, Monrovia, CA Aaron R Weiss, Maine Medical Center, Portland, ME Elizabeth R Lyden and James R Anderson, University of Nebraska Medical Center, Omaha, NE Douglas S Hawkins, Seattle Children s Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA Sheri L Spunt, St Jude Children s Research Hospital and the University of Tennessee Health Science Center, Memphis, TN David O Walterhouse, Ann and Robert H Lurie Children s Hospital of Chicago, Chicago, IL Suzanne L Wolden, Memorial Sloan Kettering Cancer Center, New York, NY David M Parham, University of Oklahoma Health Sciences Center, Oklahoma City, OK David A Rodeberg, Children s Hospital of Pittsburgh, Pittsburgh, PA Simon C Kao, University of Iowa Hospitals and Clinics, Iowa City, IA and Richard B Womer, The Children s Hospital of Philadelphia, Philadelphia, PA
    J Clin Oncol 31:3226-32. 2013
  4. pmc Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group
    David A Rodeberg
    Department of Pediatric Surgery, Children s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania
    Cancer 117:2541-50. 2011
  5. pmc Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group
    David A Rodeberg
    University of Pittsburgh School of Medicine, Department of Pediatric Surgery, Children s Hospital of Pittsburgh, Pittsburgh, PA 15213 2585, USA
    J Clin Oncol 27:3705-11. 2009

Collaborators

Detail Information

Publications5

  1. doi request reprint Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of P
    David A Rodeberg
    Department of Pediatric Surgery, Children s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA
    Int J Cancer 128:1232-9. 2011
    ..In conclusion, the majority of BP RMS patients had localized ERMS with a resultant good prognosis using current treatment algorithms. There were differences in FFS between treatment protocols but this did not result in an altered OS...
  2. pmc Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group
    David A Rodeberg
    Children s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 29:1304-11. 2011
    ..Regional lymph node disease (RLND) is a component of the risk-based treatment stratification in rhabdomyosarcoma (RMS). The purpose of this study was to determine the contribution of RLND to prognosis for patients with RMS...
  3. pmc Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee
    Aaron R Weiss
    The Soft Tissue Sarcoma Committee of the Children s Oncology Group, Monrovia, CA Aaron R Weiss, Maine Medical Center, Portland, ME Elizabeth R Lyden and James R Anderson, University of Nebraska Medical Center, Omaha, NE Douglas S Hawkins, Seattle Children s Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA Sheri L Spunt, St Jude Children s Research Hospital and the University of Tennessee Health Science Center, Memphis, TN David O Walterhouse, Ann and Robert H Lurie Children s Hospital of Chicago, Chicago, IL Suzanne L Wolden, Memorial Sloan Kettering Cancer Center, New York, NY David M Parham, University of Oklahoma Health Sciences Center, Oklahoma City, OK David A Rodeberg, Children s Hospital of Pittsburgh, Pittsburgh, PA Simon C Kao, University of Iowa Hospitals and Clinics, Iowa City, IA and Richard B Womer, The Children s Hospital of Philadelphia, Philadelphia, PA
    J Clin Oncol 31:3226-32. 2013
    ..To simplify the recommended staging evaluation by correlating tumor and clinical features with patterns of distant metastasis in newly diagnosed patients with embryonal rhabdomyosarcoma (ERMS) or alveolar rhabdomyosarcoma (ARMS)...
  4. pmc Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group
    David A Rodeberg
    Department of Pediatric Surgery, Children s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania
    Cancer 117:2541-50. 2011
    ....
  5. pmc Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group
    David A Rodeberg
    University of Pittsburgh School of Medicine, Department of Pediatric Surgery, Children s Hospital of Pittsburgh, Pittsburgh, PA 15213 2585, USA
    J Clin Oncol 27:3705-11. 2009
    ..Some patients with rhabdomyosarcoma (RMS) achieve less than a complete response (CR) despite receiving all planned therapy. We assessed the impact of best response at the completion of all therapy on patient outcome...